From the laboratory bench to the patient's bedside: An update on clinical trials with mesenchymal stem cells

By Antonio Giordano, U. Galderisi, I. Marino. Journal of Cellular Physiology, 2007

659 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/2e131e90ba2f24f6220e5bb6648a3f3e515305e1

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

In Neurology

In Surgery

Citations in the corpus

Coordinated Changes of Mitochondrial Biogenesis and Antioxidant Enzymes During Osteogenic Differentiation of Human Mesenchymal Stem Cells (2008, background): “not only to uncover the mechanisms of stemness and multi-differentiation ability of hMSCs, but also to test their potential for cell therapy and gene therapy in a number of human diseases [2].”
Intravenous hMSCs Improve Myocardial Infarction in Mice because Cells Embolized in Lung Are Activated to Secrete the Anti-inflammatory Protein TSG-6 (2009, methodology): “Currently MSCs are being employed in clin- ical trials in heart disease, Crohn’s disease, cartilage repair, stroke, spinal cord injury, and several other diseases (Prockop and Olson, 2007; Caplan, 2007; Giordano et al., 2007).”
Mesenchymal stem cell-educated macrophages: a novel type of alternatively activated macrophages (2009, background): “Currently, ex vivo culture-expanded MSCs from bone marrow, or other tissues such as adipose tissues, are being actively investigated for treatment of a variety of disorders in a multitude of several phase IIII clinical trials [19].”
Mesenchymal stem cell: an efficient mass producer of exosomes for drug delivery. (2013, background): “This could be attributed to their therapeutic efficacy in an amazingly wide spectrum of injuries and diseases [81], their easy availability in accessible and ethically palatable tissues such as bone marrow aspirate, fat tissue [82], and their large capacity for ex vivo expansion [83].”
Mesenchymal Stem Cells Are Recruited into Wounded Skin and Contribute to Wound Repair by Transdifferentiation into Multiple Skin Cell Type1 (2008, methodology): “MSCs can be considered nonhemopoietic multipotent stem-like cells that are capable of differentiating into both mesenchymal and nonmesenchymal lineages (33).”
Risk factors in the development of stem cell therapy (2011, background): “In most cases, irrespective of the treated condition or mode of administration, MSC therapy appears relatively safe [31,33,98,106].”
Hematopoietic stem cell transplantation: a global perspective. (2010, background): “Most of the 50 417 HSCTs were performed in Europe with 24 216 (48%) (median [range], 255 [6-4619] per country) followed by the Americas with 17 875 (36%) (median [range], 61 [8-15 082] per country), Asia with 7096 (14%) (median [range], 139 [5-3823] per country), and the Eastern Mediterranean and Af”
Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion (2012, background): “Mesenchymal stem cells (MSC) are considered as a potential therapy for a wide variety of degenerating and immunological disorders (Giordano et al., 2007; Reinders et al., 2010; Salem and Thiemermann, 2010).”